What is AOD-9604?
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It is discussed as a lipolytic or fat-metabolism peptide, not as full growth hormone replacement. [6][7]
Direct mechanistic support is mainly preclinical, including rodent studies of fat oxidation, lipolysis, and weight gain. Public human weight-loss support is much thinner than modern GLP-1 or incretin-drug evidence. [8][9][11]
The naming can be confusing: AOD-9604 is grouped with growth-hormone fragments, while the direct obesity literature is much smaller than approved obesity-drug evidence. [10][11][5]
What AOD-9604 is investigated for
AOD-9604 evidence is grouped by practical use case and mixed research context and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Fat breakdown and metabolism
Mixed research context
Fat breakdown and metabolism
Mixed research context
Cartilage repair and osteoarthritis
Injectable
Cartilage repair and osteoarthritis
Injectable
Cartilage repair has preclinical support for AOD-9604, but human osteoarthritis relief has not been established. [18]
Human evidence
No human osteoarthritis data establish AOD-9604 as a joint-repair treatment. [18]
Animal / mechanistic evidence
A rabbit collagenase-induced knee osteoarthritis model reported cartilage-regeneration signals after intra-articular AOD-9604, with stronger findings when combined with hyaluronic acid. [18]
Evidence snapshot
Overall confidence
AOD-9604 is not a high-confidence weight-loss peptide. The direct biology is mostly animal and mechanism work, while human efficacy support is weak and regulatory concerns are prominent. [8][11][2]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Public human weight-loss support is historically thin and does not establish a reliable obesity-treatment effect. [11][10]
Animal / preclinical
Rodent and tissue studies support biological activity around lipolysis, fat oxidation, and weight-gain models, but those findings do not establish human outcomes. [8][9][6]
Mechanism support
The mechanism rationale centers on a growth-hormone fragment domain and lipid-metabolism effects, with no modern clinical evidence package comparable to approved obesity drugs. [6][7][11]
Forms & administration
AOD-9604 has no approved-drug administration pathway. Older oral and IV development material, preclinical injection models, and current research-market injectable claims should be kept separate. [1][10][2][5]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common injectable AOD-9604 protocols usually use 300-350 mcg per dose, with broader practical ranges around 250-500 mcg. Older human development material included oral daily dosing in milligram amounts, so oral trial dosing and injectable microgram protocols should not be mixed. [10][11][2]
Frequency
Common injectable schedules are 1-2x daily. Older obesity-drug development discussions used daily dosing rather than a weekly peptide pattern. [10][11]
Timing Considerations
Morning or pre-workout are the common injectable timing anchors. The stronger practical rule is consistency; published evidence does not establish that AOD-9604 must be tied to meals, training, or sleep. [10][11]
Cycle Length
Common injectable AOD-9604 cycles are usually organized as 8-12 week blocks before reassessment. Older clinical-development material used weeks-to-months treatment windows, but long-term maintenance use is not established. [10][11]
Protocol Notes
Keep AOD-9604 route-labeled. Oral development material, injectable research-market use, and animal intra-articular cartilage models are different contexts. AOD-9604 is not an approved obesity drug, FDA flags compounded-use safety concerns, and WADA explicitly prohibits growth hormone fragments such as AOD-9604. [1][2][18][5]
What to expect
Early weeks
Early changes are more likely to look like ordinary weight fluctuation than a clear peptide-specific fat-loss effect. [11]
8-12 weeks
A clear waist or scale change is unlikely without matching nutrition and training changes, and human evidence does not support GLP-1-like weight-loss expectations. [11]
Longer term
Large or reliable fat-loss effects remain unlikely on AOD-9604 alone; any visible change is more likely to be modest and hard to separate from the rest of the routine. [11][2]
After stopping
Weight and waist are likely to keep following nutrition, training, and baseline metabolic factors after the protocol ends, because AOD-9604 has not shown a durable reset effect in humans. [11][2]
Safety profile
AOD-9604 safety handling is dominated by product and regulatory concerns: no approved product identified, FDA compounding safety risks, limited clinical usefulness, and explicit sports prohibition. [1][2][5]
Who AOD-9604 is not for
Route-specific avoid and medical-review notes:
-
Competitive athletes
AOD-9604 is explicitly prohibited under WADA growth hormone fragment language. [5]
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
Pairing notes
Not recommended with
Related peptides
Regulatory status
United States
United States: not FDA-approved for human use as a drug. FDA also identifies compounded AOD-9604 safety concerns. [1][2]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved Injectable AOD-9604 is not an FDA-approved human drug product. [1][2] | Flagged FDA lists compounded AOD-9604 among substances with potential safety risks, including immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information. [2][3] |
Injectable
International
International status varies, but sports status is not ambiguous under WADA: AOD-9604 is named as a prohibited growth hormone fragment. [5]
Sports & competition
AOD-9604 is prohibited for athletes under WADA growth hormone fragment language, and WADA has issued specific public statements on the substance. [5][4]
How it works
AOD-9604 is a growth-hormone fragment built around lipid-metabolism interest, not full GH replacement. The strongest signal is preclinical fat oxidation and lipolysis biology, which keeps the page in a low-confidence bucket. [6][8][9]
That mechanism does not establish human fat loss. Older oral, injected, and experimental contexts are not interchangeable, and the obesity-development story did not become an approved therapy. Human usefulness remains the weak link. [11][10][1]
FDA compounding concerns and WADA growth-hormone-fragment language make the mechanism a caution point, not reassurance for self-use, stacking, tested athletes, or a clinical protocol. [2][5]
Research gaps & open questions
What the current literature has not yet settled about AOD-9604:
The key clinical gap is meaningful, peer-reviewed human efficacy data showing durable weight-loss outcomes against placebo with clear dose, route, and safety reporting. [11]
Route-specific safety, immunogenicity, impurity controls, pharmacokinetics, and long-term exposure data remain insufficient for public-use confidence. [2]
Sports-risk communication should stay prominent because the anti-doping rule is clearer than the efficacy evidence. [5]
Common questions
Is AOD-9604 the same as growth hormone?
No. It is a synthetic fragment analog related to the C-terminal region of human growth hormone, not full growth hormone replacement. [6]
Does AOD-9604 work for weight loss?
Is AOD-9604 banned in sport?
Yes. WADA explicitly names growth hormone fragments including AOD-9604 in the prohibited list. [5]
Myths & misconceptions
Myth
Because AOD-9604 is only a fragment, it is automatically safe.
Reality
A smaller fragment does not eliminate product-quality, immune, regulatory, or anti-doping risks. FDA specifically flags compounded AOD-9604 safety concerns. [2]
Myth
Rodent fat-loss studies prove human fat loss.
Myth
If it is not a steroid, it is not banned.
Reality
WADA prohibits many peptide hormones, growth factors, related substances, and fragments; AOD-9604 is explicitly named. [5]
History & discovery
AOD-9604 moved from growth-hormone-fragment lipid-metabolism research into obesity-drug interest, then into anti-doping and compounding controversy. Its reputation grew wider than the human outcome evidence, so the useful history is cautionary. [6][10][11][2]
Early rodent and lipid-metabolism papers framed AOD-9604 as a synthetic growth-hormone fragment, and later development summaries described it as a metabolic obesity-drug candidate, but approval did not follow. [6][8][10][11]
WADA and FDA materials shifted the practical history toward sports eligibility, product quality, and compounding risk rather than treating the early GH-fragment mechanism as clinical validation. [4][2][5]
17 studies
openFDA Drugs@FDA query for AOD-9604
openFDA / U.S. Food and Drug Administration. database query.
Certain bulk drug substances for use in compounding may present significant safety risks
U.S. Food and Drug Administration. regulatory.
Bulk drug substances nominated for use in compounding under section 503A
U.S. Food and Drug Administration. regulatory.
WADA statement on substance AOD-9604
World Anti-Doping Agency. regulatory.
The 2026 Prohibited List
World Anti-Doping Agency, 2025. regulatory.
Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
American Journal of Physiology-Endocrinology and Metabolism. animal.
Metabolic studies of a synthetic lipolytic domain of human growth hormone in obese Zucker rats
Endocrinology / metabolic research. animal.
The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism in obese mice
Endocrinology. animal.
Increase of fat oxidation and weight loss in obese mice caused by a fragment of human growth hormone
American Journal of Physiology-Endocrinology and Metabolism. animal.
AOD-9604 Metabolic
Drugs in R&D. review.
Obesity pharmacotherapy: current perspectives and future directions
Current Obesity Reports / PMC. review.
Detection and in vitro metabolism of AOD9604
Drug Testing and Analysis. in vitro.
Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors
Obesity (Silver Spring, Md.), 2006. review.
Obesity drugs in clinical development
Current opinion in investigational drugs (London, England : 2000), 2006. review.
Gateways to clinical trials
Methods and findings in experimental and clinical pharmacology, 2005. review.
AOD-9604 does not influence the WADA hGH isoform immunoassay
Drug testing and analysis, 2013. in vitro.
Current updates in the medical management of obesity
Recent patents on endocrine, metabolic & immune drug discovery, 2012. review.